Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662325400P | 2016-04-20 | 2016-04-20 | |
PCT/US2017/028555WO2017184832A1 (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of expression-enhancing loci |
Publication Number | Publication Date |
---|---|
SG11201807885PAtrue SG11201807885PA (en) | 2018-10-30 |
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202010155YASG10202010155YA (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of expression-enhancing loci |
SG11201807885PASG11201807885PA (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of expression-enhancing loci |
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202010155YASG10202010155YA (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of expression-enhancing loci |
Country | Link |
---|---|
US (2) | US11512144B2 (en) |
EP (1) | EP3445781A1 (en) |
JP (3) | JP7096770B2 (en) |
KR (2) | KR20230098361A (en) |
CN (2) | CN109195986B (en) |
AR (1) | AR109451A1 (en) |
AU (2) | AU2017253241B2 (en) |
BR (1) | BR112018071283A2 (en) |
CA (1) | CA3015389A1 (en) |
EA (1) | EA201892010A1 (en) |
IL (2) | IL314779A (en) |
MX (1) | MX2018012868A (en) |
SG (2) | SG10202010155YA (en) |
TW (2) | TWI827531B (en) |
WO (1) | WO2017184832A1 (en) |
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10202010155YA (en)* | 2016-04-20 | 2020-11-27 | Regeneron Pharma | Compositions and methods for making antibodies based on use of expression-enhancing loci |
CN111886244A (en)* | 2017-12-22 | 2020-11-03 | 豪夫迈·罗氏有限公司 | Targeted integration of nucleic acids |
CA3123448A1 (en)* | 2018-12-21 | 2020-06-25 | Genentech, Inc. | Targeted integration of nucleic acids |
SG11202110076PA (en)* | 2019-04-02 | 2021-10-28 | Chugai Pharmaceutical Co Ltd | Method of introducing target-specific foreign gene |
CN114080454A (en) | 2019-06-26 | 2022-02-22 | 豪夫迈·罗氏有限公司 | Randomized configurational targeted integration of nucleic acids |
IL312124A (en) | 2021-10-18 | 2024-06-01 | Regeneron Pharma | Eukaryotic cells comprising adenovirus-associated virus polynucleotides |
TW202334402A (en) | 2021-10-18 | 2023-09-01 | 美商再生元醫藥公司 | Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites |
IL312148A (en) | 2021-10-18 | 2024-06-01 | Regeneron Pharma | Controlled transcription of polynucleotides |
KR20240117146A (en)* | 2021-12-22 | 2024-07-31 | 제넨테크, 인크. | Multiple vector recombinase-mediated cassette exchange |
JPWO2023238949A1 (en)* | 2022-06-10 | 2023-12-14 | ||
WO2025054526A1 (en) | 2023-09-07 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Production and purification of covalently surface modified adeno-associated virus |
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US6800457B2 (en) | 1998-09-22 | 2004-10-05 | Bristol-Myers Squibb Company | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
US6406863B1 (en) | 2000-06-23 | 2002-06-18 | Genetastix Corporation | High throughput generation and screening of fully human antibody repertoire in yeast |
CA2485939C (en) | 2002-05-29 | 2013-10-29 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
US20050019925A1 (en) | 2002-11-14 | 2005-01-27 | Genentech, Inc. | Intron fusion construct and method of using for selecting high-expressing production cell lines |
JP5620626B2 (en) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | Polypeptide production method by association control |
AU2007229698B9 (en) | 2006-03-24 | 2012-11-08 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
MY147468A (en) | 2006-06-02 | 2012-12-14 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
JP2010514416A (en) | 2006-12-21 | 2010-05-06 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | New method |
US20080216185A1 (en) | 2007-01-19 | 2008-09-04 | Invitrogen Corporation | Compositions and Methods for Genetic Manipulation and Monitoring of Cell Lines |
ES2593484T3 (en) | 2007-03-29 | 2016-12-09 | Genmab A/S | Bispecific antibodies and their production methods |
WO2008151219A1 (en)* | 2007-06-04 | 2008-12-11 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
CA2764370C (en)* | 2009-06-02 | 2018-08-21 | Regeneron Pharmaceuticals, Inc. | Fucosylation-deficient cells |
KR20120027055A (en) | 2009-06-26 | 2012-03-20 | 리제네론 파라마큐티칼스 인코포레이티드 | Readily isolated bispecific antibodies with native immunoglobulin format |
AU2010296018B2 (en) | 2009-09-16 | 2016-05-05 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
KR20120099376A (en)* | 2009-09-18 | 2012-09-10 | 셀렉시스 에스. 에이. | Products and methods for enhanced transgene expression and processing |
EA201201435A1 (en) | 2010-04-20 | 2013-04-30 | Генмаб А/С | HETERODIMERNY ANTIBODY-Fc-CONTAINING PROTEINS AND METHODS FOR THEIR RECEIVING |
PL2606064T3 (en) | 2010-08-16 | 2015-07-31 | Novimmune Sa | Methods for the generation of multispecific and multivalent antibodies |
TW201823460A (en) | 2012-05-29 | 2018-07-01 | 美商再生元醫藥公司 | Production cell line enhancers |
EP2711428A1 (en) | 2012-09-21 | 2014-03-26 | Lonza Biologics plc. | Site-specific integration |
US20150203591A1 (en)* | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
JOP20200236A1 (en) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof |
TWI745610B (en) | 2012-11-14 | 2021-11-11 | 美商再生元醫藥公司 | Recombinant cell surface capture proteins |
TWI635098B (en) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | Antibodies comprising chimeric constant domains |
US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
TWI670283B (en) | 2013-12-23 | 2019-09-01 | 美商建南德克公司 | Antibodies and methods of use |
TWI701042B (en) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | Methods and antibody compositions for tumor treatment |
SG11201703149RA (en) | 2014-10-23 | 2018-02-27 | Regeneron Pharma | Novel cho integration sites and uses thereof |
MY195059A (en) | 2015-09-23 | 2023-01-05 | Regeneron Pharma | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof |
SG10202010155YA (en)* | 2016-04-20 | 2020-11-27 | Regeneron Pharma | Compositions and methods for making antibodies based on use of expression-enhancing loci |
Publication number | Publication date |
---|---|
US20190233544A1 (en) | 2019-08-01 |
US11512144B2 (en) | 2022-11-29 |
EA201892010A1 (en) | 2019-03-29 |
MX2018012868A (en) | 2019-03-11 |
CN116515757A (en) | 2023-08-01 |
KR20180134893A (en) | 2018-12-19 |
IL314779A (en) | 2024-10-01 |
TWI827531B (en) | 2024-01-01 |
CA3015389A1 (en) | 2017-10-26 |
CN109195986B (en) | 2023-01-03 |
US20230130799A1 (en) | 2023-04-27 |
IL262266B1 (en) | 2024-09-01 |
SG10202010155YA (en) | 2020-11-27 |
IL262266B2 (en) | 2025-01-01 |
JP2019515666A (en) | 2019-06-13 |
JP7096770B2 (en) | 2022-07-06 |
BR112018071283A2 (en) | 2019-02-12 |
KR20230098361A (en) | 2023-07-03 |
CN109195986A (en) | 2019-01-11 |
WO2017184832A1 (en) | 2017-10-26 |
KR102547738B1 (en) | 2023-06-26 |
AU2017253241A1 (en) | 2018-09-20 |
AU2017253241B2 (en) | 2024-07-04 |
JP2021164479A (en) | 2021-10-14 |
AU2024220124A1 (en) | 2024-10-17 |
TW201803986A (en) | 2018-02-01 |
JP2024023449A (en) | 2024-02-21 |
AR109451A1 (en) | 2018-12-12 |
EP3445781A1 (en) | 2019-02-27 |
IL262266A (en) | 2018-11-29 |
TW202415767A (en) | 2024-04-16 |
Publication | Publication Date | Title |
---|---|---|
SG11201807885PA (en) | Compositions and methods for making antibodies based on use of expression-enhancing loci | |
SG11201807881VA (en) | Compositions and methods for making antibodies based on use of an expression-enhancing locus | |
SG11201909203WA (en) | Tissue selective transgene expression | |
SG11201810327XA (en) | Single domain serum albumin binding protein | |
SG11201807187XA (en) | Binding members to pd-l1 | |
SG11201900201YA (en) | Methods for quantitating individual antibodies from a mixture | |
SG11202000073XA (en) | Anti-cd8 antibodies and uses thereof | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201906341XA (en) | Improved serum albumin binders | |
SG11201811270WA (en) | Systems and methods for trajectory determination | |
SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
SG11201909432SA (en) | Compounds for increasing genome editing efficiency | |
SG11201807794VA (en) | Naphthene-containing distillate stream compositions and uses thereof | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201808398PA (en) | Cell line for recombinant protein and/or viral vector production | |
SG11201810777WA (en) | Purification of multispecific antibodies | |
SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
SG11201908784TA (en) | Improved antigen binding receptor formats | |
SG11201808476SA (en) | Recycling of polymer matrix composite | |
SG11201805950UA (en) | Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them | |
SG11201809793UA (en) | Tl1a antibodies and uses thereof | |
SG11201807474SA (en) | Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies |